Short Interest in Enliven Therapeutics, Inc. (NASDAQ:ELVN) Expands By 9.7%

Enliven Therapeutics, Inc. (NASDAQ:ELVN) saw a significant growth in short interest in the month of April. As of April 15th, there was short interest totalling 4,640,000 shares, a growth of 9.7% from the March 31st total of 4,230,000 shares. Currently, 18.3% of the shares of the company are sold short. Based on an average daily volume of 247,800 shares, the short-interest ratio is currently 18.7 days.

Insider Activity at Enliven Therapeutics

In other news, insider Joseph P. Lyssikatos sold 30,000 shares of the business’s stock in a transaction dated Thursday, April 11th. The stock was sold at an average price of $25.04, for a total value of $751,200.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, CEO Samuel Kintz sold 12,000 shares of the firm’s stock in a transaction on Thursday, April 25th. The shares were sold at an average price of $16.89, for a total transaction of $202,680.00. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider Joseph P. Lyssikatos sold 30,000 shares of the company’s stock in a transaction dated Thursday, April 11th. The stock was sold at an average price of $25.04, for a total transaction of $751,200.00. The disclosure for this sale can be found here. Insiders sold 742,266 shares of company stock worth $12,891,980 over the last three months. Company insiders own 45.80% of the company’s stock.

Hedge Funds Weigh In On Enliven Therapeutics

A number of hedge funds have recently made changes to their positions in the company. AJOVista LLC purchased a new stake in shares of Enliven Therapeutics during the fourth quarter worth $28,000. China Universal Asset Management Co. Ltd. purchased a new stake in Enliven Therapeutics during the 4th quarter valued at about $66,000. Exchange Traded Concepts LLC raised its holdings in Enliven Therapeutics by 34.0% in the 4th quarter. Exchange Traded Concepts LLC now owns 8,708 shares of the company’s stock valued at $121,000 after acquiring an additional 2,208 shares during the last quarter. SG Americas Securities LLC purchased a new position in Enliven Therapeutics in the 3rd quarter worth approximately $157,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its stake in Enliven Therapeutics by 9.1% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 12,305 shares of the company’s stock worth $170,000 after purchasing an additional 1,029 shares in the last quarter. Institutional investors and hedge funds own 95.08% of the company’s stock.

Analyst Ratings Changes

Separately, Mizuho initiated coverage on Enliven Therapeutics in a research note on Tuesday, April 9th. They set a “buy” rating and a $34.00 target price for the company.

Enliven Therapeutics Stock Up 3.6 %

ELVN opened at $17.79 on Tuesday. The firm’s fifty day simple moving average is $17.14 and its two-hundred day simple moving average is $14.53. Enliven Therapeutics has a 52-week low of $9.80 and a 52-week high of $26.00.

Enliven Therapeutics (NASDAQ:ELVN) last released its quarterly earnings results on Thursday, March 14th. The company reported ($0.47) earnings per share for the quarter, topping the consensus estimate of ($0.56) by $0.09. Equities research analysts expect that Enliven Therapeutics will post -2.16 EPS for the current year.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.